SCHEMBL29454100

SCHEMBL29454100

Cc1cc(N)c(Cl)c(Nc2ncccc2C(F)(F)F)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
POLB P06746 1/20 0.41
RAPGEF3 O95398 1/20 0.38
ALDH1A1 P00352 2/20 0.36
HPGD P15428 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36
LMNA P02545 1/20 0.36
KMT2A Q03164 1/20 0.36
EGFR P00533 1/20 0.36
GRM4 Q14833 2/20 0.34
CNR2 P34972 1/20 0.34
P2RY1 P47900 1/20 0.34
CYP1A2 P05177 1/20 0.33
TSHR P16473 1/20 0.33
HIF1A Q16665 1/20 0.33
RAPGEF4 Q8WZA2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22232038 1.00 DHODH (0.43) DHODHHDAC6POLBRAPGEF3ALDH1A1
SCHEMBL31723213 1.00 DHODH (0.43) DHODHHDAC6POLBRAPGEF3ALDH1A1
SCHEMBL29454077 0.83 RAB9A (0.43) ALDH1A1HPGDRAB9ASMN1; SMN2KDM4E
SCHEMBL22232392 0.83 RAB9A (0.43) ALDH1A1HPGDRAB9ASMN1; SMN2KDM4E
SCHEMBL31723212 0.83 RAB9A (0.43) ALDH1A1HPGDRAB9ASMN1; SMN2KDM4E
SCHEMBL22232298 0.76 DHODH (0.46) DHODHHDAC6POLBRAPGEF3EGFR
SCHEMBL29454148 0.76 DHODH (0.46) DHODHHDAC6POLBRAPGEF3EGFR
SCHEMBL22231764 0.75 POLB (0.37) DHODHHDAC6POLBRAPGEF3KMT2A
SCHEMBL22231767 0.75 POLB (0.37) DHODHHDAC6POLBRAPGEF3KMT2A
SCHEMBL22232146 0.75 PLAU (0.37) POLBALDH1A1RAB9ASMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12545639-B2 3-substituted phenylamidine compounds, preparation and use thereof PI INDUSTRIES LTD. (IN) 2026-02-10 US claimed
US-20220089523-A1 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF PI INDUSTRIES LTD. (IN) 2022-03-24 US claimed
US-12545639-B2 3-substituted phenylamidine compounds, preparation and use thereof PI INDUSTRIES LTD. (IN) 2026-02-10 US disclosed
EP-4647426-A2 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF PI Industries Ltd. (IN) 2025-11-12 EP disclosed
US-20220089523-A1 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF PI INDUSTRIES LTD. (IN) 2022-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220089523-A1 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF H1-3, PRMT7, PFAS DHODH 3858/4885HDAC6 2245/4885POLB 2700/4885
US-12545639-B2 3-substituted phenylamidine compounds, preparation and use thereof CBR1, CBR3, HCCS DHODH 4076/4885HDAC6 3181/4885POLB 4520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.